tbuckley/cabot-search huggingface dataset:
The Need for Ergonomics Education in Dermatology and Dermatologic Surgery
Authors: Ashish C. Bhatia, Shuai Xu, June K. Robinson
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
PTU-137 Enhanced Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by History and Diagnostic Evaluation: Abstract PTU-137 Table 1
Authors: R Sood, M Camilleri, DJ Gracie, MJ Gold, N To, GR Law, AC Ford
Journal: Gut (2016)

<h3>Introduction</h3> Symptom-based criteria to diagnose irritable bowel syndrome (IBS) positively perform only modestly. Our aim was to assess whether including other items from the clinical history and diagnostic workup improves their performance. <h3>Methods</h3> We collected complete symptom, colonoscopy, and histology data from 318 consecutive, unselected adult patients with lower gastrointestinal (GI) symptoms in secondary care. The reference standard used to define presence of true IBS was patient-reported lower abdominal pain or discomfort associated with a change in bowel habit, in the absence of organic GI disease. Sensitivity, specificity, and positive and negative likelihood ratios (LRs), with 95% confidence intervals, were calculated for Rome III criteria, as well as for modifications, incorporating nocturnal symptoms, results of simple blood tests (haemoglobin (Hb) and C-reactive protein (CRP)), measures of somatisation, and/or affect (hospital anxiety or depression scale (HADS) score). <h3>Results</h3> Sensitivity and specificity of Rome III criteria for identifying IBS was 69.6%, and 82.0% respectively, with positive and negative LRs of 3.87 and 0.37. Clinically useful enhancements in positive LRs when combining Rome III criteria with items from the clinical history, and blood tests, are shown in the table. <h3>Conclusion</h3> Incorporating nocturnal symptoms, somatisation, and affect from the clinical history, and haemoglobin and CRP measurements, enhances performance of symptom-based criteria for IBS. Our findings suggest a different approach to the development of future diagnostic criteria should be used. <h3>Disclosure of Interest</h3> None Declared
Interim Anaiysis of Intention To Treat Analysis, “Multicenter AML-2000 Trial” Based on Cytogenetics Risk Factors.
Authors: Yeung-Chul Mun, S.M. Lee, S.M. Bang, S.H. Park, E.K. Cho, J.H. Lee, D.Y. Jo, S.Y. Kim, I.H. Kim, S.S. Yoon, S.Y. Park, B.K. Kim, Y.J. Min, J.J. Seo, Thad Ghim, M.H. Lee, C.S. Kim, Y.D. Joo, S.Y. Chung, D.Y. Oh, J.S. Ahn, D.Y. Zang, K.H. Lee, M.K. Kim, M.S. Hyun, H.S. Song, H.S. Kim, H.C. Kwon, H.J. Kim, K.T. Park, S.H. Bae, H.M. Ryoo, M.J. Ahn, H.J. Yoon, B.S. Kim, Y.H. Park, C.M. Seong
Journal: Blood (2005)
PWE-024 Early Change in Faecal Calprotectin Predicts Primary Non- Response to Anti-TNFΑ Therapy in Inflammatory Bowel Disease
Authors: P Pavlidis, S Gulati, P Dubois, G Chung-Faye, J Tumova, L Medcalf, LM Choong, R Sherwood, I Bjarnason, B Hayee
Journal: Gut (2016)

<h3>Introduction</h3> The early identification of primary non-response to anti-TNFα therapy facilitates the timely management of patients with inflammatory bowel disease (IBD). A recent, pilot study to detect prognostic markers of early response to anti-TNFα therapy identified the two genes coding for the calprotectin subunits (S100A8, S100A9) to be among the most highly expressed gene transcripts in non-responders. This study tests the hypothesis that measurements of faecal calprotectin (FCAL) pre- and post- anti-TNFα induction can predict primary non-response in both Crohn’s disease (CD) and ulcerative colitis (UC) <h3>Methods</h3> Retrospective study of 32 CD and 18 UC patients treated over a two-year period. Outcomes were assessed using Harvey-Bradshaw Index (HBI) or Simple Clinical Colitis Activity Index (SCCAI) (response: drop in HBI/SCCAI &gt;3, remission: HBI &lt; 5, SCCAI &lt;3, steroid free) at 6 months. ΔFCAL was calculated as (FCALpost induction – FCALpre induction)*100/FCAL pre induction. <h3>Results</h3> At 6 months, 23 (72%) CD and 10 (56%) UC patients had responded. In remission were 17 (53%) and 5 (28%) respectively. Comparing non-responders to combined response and remission groups, the area under the curve of ΔFCAL to predict outcomes at 6 months was 0.97 for CD and 0.96 for UC. Using ROC analysis, a decrease of 70% returned a sensitivity and specificity of 99% and 96%, respectively (likelihood ratio, LR = 23) in CD. For UC a a decrease of 70% had a sensitivity and specificity of 88% and 86%, respectively (LR = 6). <h3>Conclusion</h3> A drop in FCAL &lt; 70% after induction predicts primary non-response to anti-TNFα in both CD and UC. <h3>Disclosure of Interest</h3> None Declared
Sport climbing: medical considerations for this new Olympic discipline
Authors: C Lutter, Y El-Sheikh, I Schöffl, V Schöffl
Journal: British Journal of Sports Medicine (2016)

Since the recent announcement that Sport Climbing was selected to be part of the next Summer Olympic Games in 2020, climbers around the world are eager to see their sport on the most world-renowned athletic stage. A few days ago, the Tokyo 2020 Additional Event Programme Panel selected this very exciting and challenging sport, with its three subdisciplines (‘Lead Climbing’, ‘Speed Climbing’ and ‘Bouldering’), to be part of the next Summer Olympics. This landmark decision reflects a huge worldwide interest and enthusiasm for the relatively young sport of climbing, which has exploded in popularity in recent years.

This is an exciting time for sport climbers, coaches and fans; however, we would like to recommend a cautious and informed approach to establishing this sport as part of the Olympic …
The state of UK medical education and practice: report from the GMC
Authors: Abi Rimmer
Journal: BMJ (2016)

The General Medical Council recently published its sixth annual report on the state of medical education and practice.1 Here are five things the report told us

From 2011 to 2015 there was a 22% rise in the number of specialists who described themselves as black and minority ethnic (BME) and an 18% increase in the …
Body-mass index and cardiometabolic disease: a Mendelian randomisation study of UK Biobank participants
Authors: Donald M Lyall, Carlos Celis-Morales, Joey Ward, Stamatina Iliodromiti, Jana J Anderson, Jason M R Gill, Daniel J Smith, Uduakobong Efanga Ntuk, Daniel F Mackay, Michael V Holmes, Naveed Sattar, Jill P Pell
Journal: The Lancet (2016)
SAT0191 Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution To Human Systemic Sclerosis Fibrosis
Authors: M.-E. Truchetet, B. Demoures, J. Guimaraes, A. Bertrand, P. Laurent, I. Douchet, P. Duffau, E. Lazaro, C. Richez, J. Seneschal, J. Constans, J.-L. Pellegrin, T. Schaeverbeke, P. Blanco, C. Contin-Bordes
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic sclerosis (SSc) is a complex systemic autoimmune disease characterized by microvascular dysfunction, immune activation and fibrosis affecting the skin and internal organs (1). Improved characterization of the fibrotic mechanisms involved in SSc is a keystone to developing biomarkers and effective disease-modifying therapies. The activation of endothelial cells (ECs) appears very early in the course of the disease, suggesting that chronic fibroblast activation may be at least partly the result of endothelial dysfunction (1,2). However, the ability of the platelet/EC interaction to induce the secretion of factors directly involved in fibroblast activation and subsequent fibrosis in SSc remains uncertain. <h3>Objectives</h3> The objective was to provide evidence of a new pathogenic loop implicating activated platelets, microvascular ECs and ECM production in SSc. <h3>Methods</h3> A total of 203 SSc patients and 30 healthy donors (HDs) were prospectively enrolled between March 2012 and January 2015 at the University Hospital of Bordeaux. Immunohistochemistry and immunofluorescence analysis were performed on skin biopsy specimens from 18 SSc patients and 5 HDs. Serum TSLP levels were measured (ELISA) in the entire cohort. Human dermal microvascular ECs and fibroblasts were purified from normal and SSc patients skin biopsies. Extracellular matrix production by cultured fibroblasts was assessed by RT-qPCR. <h3>Results</h3> Serum TSLP levels were significantly increased in SSc patients compared to HDs (p=0.0005) and were associated with a higher frequency of vascular damage (p=0.02). The proportion of dermal TSLP-positive cells was increased in the skin biopsies of SSc patients compared to HDs (p=0.0008) and was correlated with skin fibrosis (modified Rodnan skin score) (R=0.059, p=0.01). In SSc dermis, TSLP was mainly expressed by CD31-positive ECs. In vitro, activated platelets induced TSLP production by dermal microvascular ECs in an IL1β-dependent manner. Recombinant TSLP in normal fibroblasts reproducibly induced a pro-fibrotic profile as indicated by a significant increase in the collagen/collagenase ratio (p=0.03). Interestingly, this property was shared by fibroblasts purified from non-fibrotic TSLP-negative SSc skin, but lost with fibroblasts purified from TSLP-positive fibrotic skin. <h3>Conclusions</h3> Taken together, these results identify dermal microvascular ECs as new contributors to TSLP production in SSc and suggest a potential mechanism by which platelets may profoundly affect the fibrotic process in SSc. <h3>References</h3> Gabrielli A, et al., N Engl J Med 2009. Pattanaik D, et al., Front Immunol 2015. <h3>Disclosure of Interest</h3> None declared
Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis
Authors: Floor A.C. Berden, Bryan R.R.Z. Aaldering, Hans Groenewoud, Joanna IntHout, Wietske Kievit, Joost P.H. Drenth
Journal: Clinical Gastroenterology and Hepatology (2016)
Suicide Attempts Among US Army Soldiers
Authors: Xiulu Ruan, Srinivas Chiravuri, Alan D. Kaye
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Low-Dose Prednisone Decreases the Severity but Not the Frequency of Lenalidomide Associated Tumor Flare Feaction (TFR) in Chronic Lymphocytic Leukemia (CLL) Patients.
Authors: Laurie Musial, Kena C. Miller, Amy Tonelli, Rami Manochakian, Swaminathan Padmanabhan, David Lawrence, Dawn DePaolo, Jean-Gabriel Coignet, Asher Alban Chanan-Khan
Journal: Blood (2006)
Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non−Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant
Authors: Kylie Lepic, Ann Benger, Ronan Foley, Graeme Fraser, Deborah Marcellus, Michelle Saunders-Roy, Michael Trus, Anita Adams, Kari Kolm, Jennifer Wiernikowski, C. Tom Kouroukis
Journal: Blood (2011)
CD169+ Macrophages Regulate Erythropoiesis Under Homeostasis, Recovery From Erythron Injury and in JAK2V617F-Induced Polycythemia Vera
Authors: Andrew Chow, Matthew Huggins, Jalal Ahmed, Daniel Lucas, Daigo Hashimoto, Yuya Kunisaki, Sandra Pinho, Marylene Leboeuf, Clara Noizat, Nico van Rooijen, Masato Tanaka, Zhizhuang Joe Zhao, Aviv Bergman, Miriam Merad, Paul S. Frenette
Journal: Blood (2012)
Higher Bone Marrow Lymphocyte Percentage 3 to 6 Month After Therapy with Hypercvad + Dasatinib Than That with Hypercvad + Imatinib or Hypercvad Alone In Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Authors: Mouhammad Kheder, Farhad Ravandi, Hagop Kantarjian, Jorge E. Cortes, Susan O'Brien, Deborah A Thomas, Stefan Faderl
Journal: Blood (2010)
SAT0241 Observational Study of Seasonal Monthly Infusions of Iloprost –Experience from A Regional Centre in UK:
Authors: P. Joshi, S. Venkatachalam, T. Sheeran
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Iloprost (Prostacyclin) is effective for resistant Raynaud9s phenomenon. We describe our practice of seasonal once monthly infusion which is more cost-effective and flexible than the usual practice of giving iloprost for 3 to 5 days. <h3>Objectives</h3> To identify the characteristics, response and tolerance of patients on seasonal monthly infusions of Iloprost from a regional centre in Cannock, United Kingdom. <h3>Methods</h3> Retrospective data analysis of patients having monthly iloprost infusions before and during winter for 3–4 months a year (November to February) for resistant Raynaud9s phenomenon in 2013 and 2014. <h3>Results</h3> There were 72 patients; 57 females and 15 males (F/M =3.8/1), with a mean age of 50.2 (±15.1) years at the start of the iloprost infusion. Underlying diagnosis: Sixty-four patients (88.9%) received calcium channel blockers like nifedipine prior to iloprost and 2 of them also had sildenafil. Thirteen (18.1%) patients had iloprost for 3 to 5 days before switching to seasonal monthly treatment; 8 of them had a digital ulcer or gangrene at presentation. Average follow up was 3.4 (± 2.3) years and mean number of infusions/patient/year was 3.28 ± 0.98.Iloprost improved Raynaud9s symptoms in winter in all the patients and was well tolerated by most. Dose adjustment of the iloprost was necessary in 6 (8.3%) patients while 5 (6.9%) of them discontinued due to intolerance. <h3>Conclusions</h3> Monthly seasonal iloprost during winter is effective and well tolerated in patients with resistant Raynaud9s phenomenon. It is also less expensive than longer courses of iloprost. <h3>Disclosure of Interest</h3> None declared
Fingolimod (FTY720) Overcomes the Resistance to Tyrosine Kinase Inhibitors Via Dual Activation of BIM and BID in Chronic Myelogenous Leukemia
Authors: Miki Kiyota, Junya Kuroda, Mio Yamamoto-Sugitani, Yuji Shimura, Ryuko Nakayama, Hisao Nagoshi, Shinsuke Mizutani, Yoshiaki Chinen, Natsumi Sakamoto, Tsutomu Kobayashi, Yosuke Matsumoto, Shigeo Horiike, Tomohiko Taki, Masafumi Taniwaki
Journal: Blood (2012)
THU0285 Dalazatide, An Inhibitor of The Kv1.3 Channel on Activated Effector Memory T Cells, Has Immunotherapy Potential in Systemic Lupus Erythematosus
Authors: A.M. Stevens, M. Yuasa, D. Peckham, C. Olsen, S.P. Iadonato, P. Probst
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> T cell activation depends upon a calcium signaling cascade that is regulated by voltage-gated potassium channels. Effector memory T cells (T<sub>EM</sub>), which are implicated in the immunopathogenesis of a panel of autoimmune diseases, express the potassium channel Kv1.3. Dalazatide is a potent peptide inhibitor of the Kv1.3 channel that has recently shown efficacy in a Phase 1b plaque psoriasis trial. Evidence suggests that inflammatory cytokine producing T<sub>EM</sub> cells might be involved in the immunopathology of lupus nephritis. <h3>Objectives</h3> Provide proof-of-principle <i>ex vivo</i> data for therapeutically targeting chronic T cell activation in systemic lupus erythematosus (SLE) by using dalazatide to block the Kv1.3 channel and to evaluate the effect of dalazatide on the <i>in vitro</i> inflammatory cytokine production of T<sub>EM</sub> cells from SLE patients. <h3>Methods</h3> Peripheral blood mononuclear cells from pediatric and adult SLE patients as well as healthy controls were studied. T lymphocyte subsets were assayed <i>ex vivo</i> for Kv1.3 expression by flow cytometry. The effect of dalazatide on phorbol myristate acetate (PMA)/ionomycin-induced inflammatory cytokine expression by T<sub>EM</sub> cells was evaluated by intracellular cytokine staining. <h3>Results</h3> Kv1.3 expression by CD8<sup>+</sup> T<sub>EM</sub> cells was significantly higher in patients with active lupus nephritis when compared to patients with inactive SLE or healthy controls. Dalazatide inhibited IFN-γ, IL-17 and TNF-α production by both CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>EM</sub> cells from SLE patients in a dose-dependent manner. Higher levels of dalazatide-mediated inhibition were observed in IFN-γ and TNF-α-expressing CD4<sup>+</sup> T<sub>EM</sub> cells from patients with active SLE when compared to samples from SLE patients with inactive disease. <h3>Conclusions</h3> <i>Ex vivo</i> studies suggest that dalazatide inhibition of Kv1.3 may be a therapeutic target for SLE. In addition, Kv1.3 expression may be a useful biomarker of disease activity in SLE. <h3>Disclosure of Interest</h3> A. Stevens Grant/research support from: Kineta, Inc., M. Yuasa Grant/research support from: Kineta, Inc., D. Peckham Grant/research support from: Kineta, Inc., Employee of: Kineta, Inc., C. Olsen Grant/research support from: Kineta, Inc., Employee of: KPI Therapeutics, Inc, S. Iadonato Grant/research support from: Kineta, Inc., Employee of: Kineta, Inc., P. Probst Grant/research support from: Kineta, Inc., Employee of: Kineta, Inc.
AB0827 High Prevalence of Hallux Valgus in Gouty Patients Requiring Urate Lowering Therapy
Authors: C. Blandin, M. Forien, P. Dieudé, S. Ottaviani
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Hallux valgus (HV) is a common pathology leading to pain and deformation of the first metatarsophalangeal joint (MTP1). Gout preferentially affects MTP1 joint and gives disability and pain. It was suggested that gouty patients could have more severe hallux valgus. <h3>Objectives</h3> We aimed to determine: 1) the prevalence of HV in gouty patient starting urate lowering therapy (ULT) and 2) the potential factors associated with HV. <h3>Methods</h3> In this transversal single center study, we included patient with proven gout (presence of monosodic urate crystal in synovial fluid) requiring ULT. All patients underwent ultrasonography of MTP1s and radiography of the feet. Demographic and clinical characteristics were collected for each patient. Serum uric-acid (SUA) level was assessed at baseline. One trained ultrasonographer, blinded to radiographic measure, assessed at the MTP1 joints, US-evidenced urate deposits (double contour [DC] sign and/or tophi) before starting ULT. HV was analyzed, blinded to clinical and US data, according to the radiographic measure of hallux abductus (HA) angle, and the intermetatarsal (IM) angle. HV was defined by HA angle ≥20° and/or IM angle ≥10°. Correlation between US findings and different HV angles was estimated by the Spearman coefficient of correlation. <h3>Results</h3> A total of 43 patients (93% of male patients) with untreated proven gouty patients were studied. The median age was 63.0 [IQR 57.0–73.0] years old. Median disease duration was 3.0 [1.0–6.0] years. Clinical tophi were found in 24% of patients. The median MDRD creatinin clearance and serum uric acid level were 63.0 [IQR 39.8–78.0] ml/mn/1.73m<sup>2</sup> and 507 [IQR 446–601] μmol/l, respectively. Ultrasound assessment of MTP1 joints revealed a DC sign and tophus in 59.3% and 69.8% of joints, respectively. The median size of US tophi were 11.7 [IQR 9.4–13.7] mm. Radiography found HV in 61.9% of feets (72% of patients). The median IM and HA angles were 8.9 [IQR 7.0–10.0] mm and 20.5 [IQR 15.1–26.0] mm, respectively. The percentage of MTP1 joints with US tophus or DC sign was not significantly higher in patients with HV. No correlation was found between the size of US tophus and HA angle (<i>P</i>=0.54). However, IM angle tended to be correlated with the size of US tophus (<i>P</i>=0.08). We did not observe any correlation between age, gender, SUA levels, presence of clinical tophus, creatinine clearance, disease duration, number of attacks and presence of HV. <h3>Conclusions</h3> Our results suggest a high prevalence of HV in gouty patients requiring ULT. Despite a tendency to have an association between US tophus size and IM angle, we did not observed any correlation between size of tophus and presence of HV. Our patients having a long disease duration, we might hypothesize that a sooner treatment could prevent the apparition of HV in these patients. <h3>Disclosure of Interest</h3> None declared
Neurotrophic Bone Marrow Cellular Nests Prevent Spinal Motoneuron Degeneration in Amyotrophic Lateral Sclerosis Patients
Authors: Miguel Blanquer Blanquer, Francisca Iniesta, Joaquín Gómez Espuch, Villaverde Ramón, Miguel Ángel Pérez Espejo, Francisco José Ruíz López, José María García Santos, Patricia Bleda, Virginia Izura, María Vicenta Sáez, Pedro de Mingo, Laura Vivancos, Rafael Carles, Maria Juliana Majado, Andrés Sánchez Salinas, Juan Francisco Martínez-Lage, Salvador Martínez, José M. Moraleda
Journal: Blood (2011)
Structural Comparability Between Recombinant FVIII-Fc and Its Isolated FVIII and Fc Constituents
Authors: John Kulman, Susan Tsutakawa, George Bou-Assaf, Steven Berkowitz, David R. Light, Adam Mezo, Deping Wang, Marc Whitlow, Liz Culyba, John Tainer, Robert Peters
Journal: Blood (2012)
Genomic and Proteomic Signatures of Human Mesenchymal Stem Cells.
Authors: Wolfgang Wagner, Robert E. Feldmann, Frederik Wein, Anja Seckinger, Ulf Krause, Maria Frankhauser, Martin H. Maurer, Jonathon Blake, Volker Eckstein, Rainer Saffrich, Patrick Wuchter, Wolfgang Kuschinsky, Anthony D. Ho
Journal: Blood (2005)
Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE ® Antibody Blinatumomab.
Authors: Gerhard Zugmaier, Dirk Nagorsen, Matthias Klinger, Ralf C Bargou, Mariele Goebeler, Andreas Viardot, Patrick A Baeuerle, Peter Kufer
Journal: Blood (2009)
Prophylactic Low Molecular Weight Heparin (LMWH) during Pregnancy Is Not Associated with a Decrease in Bone Mineral Density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD Substudy.
Authors: Marc A. Rodger, Alejandro Lazo-Langner, Susan Kahn, Michael Kovacs, Sue Robinson, Mark Blostein, Graeme Smith, John Kingdom, Christine Demers, Susan Solymoss, Rshmi Khurana, Evelyn Rey, Anne Marie Clement, Philip S. Wells
Journal: Blood (2005)